Mystakidou Kyriaki, Panagiotou Irene, Brountzos Elias, Kouloulias Vassilios, Gouliamos Athanasios
Pain Relief and Palliative Care Unit, First Department of Radiology, Areteion Hospital, University of Athens, School of Medicine, Greece.
Onkologie. 2011;34(12):706-9. doi: 10.1159/000334551. Epub 2011 Nov 21.
Well-differentiated liposarcomas of the upper extremities, such as the hand or forearm, are extremely rare and are commonly misdiagnosed and considered benign. They are frequently reported as having low metastatic potential.
We report the case of a 58-year-old man with well-differentiated hand liposarcoma and diffuse bone metastases. The patient initially presented with a tumor of the thenar eminence and was treated with marginal surgical excision and external beam irradiation. 4 months after this treatment, soft tissue local recurrence and skeletal metastases were detected. Zoledronic acid treatment (4 mg per month) was initiated, and both the tumor and the metastases regressed. The patient remains cancer-free 3.5 years after diagnosis of the metastatic disease.
Significant metastatic disease can develop in patients with well-differentiated liposarcomas. The beneficial effect of zoledronic acid observed in this case may be related to its anticancer properties, as described in phase III trials in various tumor types.
上肢（如手部或前臂）的高分化脂肪肉瘤极为罕见，常被误诊为良性。它们通常被报道为转移潜能较低。
我们报告一例58岁男性患有高分化手部脂肪肉瘤并伴有弥漫性骨转移的病例。患者最初表现为鱼际隆起处的肿瘤，接受了边缘性手术切除和外照射治疗。该治疗4个月后，检测到软组织局部复发和骨骼转移。开始使用唑来膦酸治疗（每月4毫克），肿瘤和转移灶均消退。在诊断为转移性疾病3.5年后，患者仍无癌。
高分化脂肪肉瘤患者可能发生显著的转移性疾病。本病例中观察到的唑来膦酸的有益作用可能与其抗癌特性有关，如在各种肿瘤类型的III期试验中所描述的那样。
